Showing results (171-180 of 184) with videos related to
Sort By:
Pageof 19
Biochemistry|December 24, 1991
Fidelity of mammalian DNA replication and replicative DNA polymerasesD C Thomas, J D Roberts, R D Sabatino, et al.Cancer Research|October 1, 1990
Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancerJ A Stewart, J L Belinson, A L Moore, et al.The Journal of Biological Chemistry|December 16, 1998
Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMPJ D Chiche, S M Schlutsmeyer, D B Bloch, et al.Clinical Genetics|August 15, 2012
Detection of genomic deletions of PKP2 in arrhythmogenic right ventricular cardiomyopathyJ D Roberts, J C Herkert, J Rutberg, et al.British Journal of Cancer|September 16, 2010
Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in miceT Matsuoka, J E Adair, F B Lih, et al.Pediatrics|June 1, 1990
Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome. Ross Collaborative Surfactant Prevention Study GroupR F Soll, R E Hoekstra, J J Fangman, et al.Cancer Research|September 1, 1988
Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 scheduleJ A Stewart, J J McCormack, W Tong, et al.Genomics|June 10, 1995
Three members of the nitric oxide synthase II gene family (NOS2A, NOS2B, and NOS2C) colocalize to human chromosome 17K D Bloch, J R Wolfram, D M Brown, et al.International Journal of Radiation Oncology, Biology, Physics|March 10, 2001
A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamicsB D Kavanagh, S R Khandelwal, R K Schmidt-Ullrich, et al.Cancer Chemotherapy and Pharmacology|May 10, 2000
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeksJ D Roberts, S Shibata, D V Spicer, et al.Pageof 19